文献速递腹部技术与安全MRCTPET

结直肠癌KRAS突变影像组学预测研究的现状与质量:系统综述与荟萃分析

Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: A systematic review and meta‑analysis.
PubMed 文献 · Eur J Radiol · 2022-12-09

平均RQS评分为9.55(总分26.5%),荟萃分析显示训练队列汇总敏感度0.80、特异度0.80、AUC 0.87,验证队列分别为0.78、0.84、0.86。结论认为影像组学对KRAS突变有中等术前预测效能,但尚未达到临床决策工具水平。

要点

  • 影像组学预测KRAS突变训练队列AUC 0.87、验证队列AUC 0.86,属中等效能。
  • 研究平均RQS评分仅9.55(总分26.5%),方法学质量普遍不高。
  • 多数研究偏倚风险低或不清楚,但需多中心外部验证才能推向临床。

核心结论

  • 影像组学作为一种无创技术,对结直肠癌KRAS突变具有中等的术前诊断和预测效果,但尚未作为临床决策工具实施。

研究设计与样本

  • 采用QUADAS-2和影像组学质量评分(RQS)评估方法学质量,RQS平均9.55分(总分26.5%),范围3至17分。
  • 荟萃分析中多数研究使用MRI成像,其次为CT和PET/CT;参考标准为KRAS突变状态。

诊断标准与关键数值

  • 训练队列汇总敏感度0.80(95%CI 0.75-0.84),特异度0.80(95%CI 0.74-0.85),AUC 0.87(95%CI 0.84-0.90)。
  • 验证队列(13项研究)汇总敏感度0.78(95%CI 0.71-0.84),特异度0.84(95%CI 0.74-0.90),AUC 0.86(95%CI 0.83-0.89)。

临床应用与阅片要点

  • 影像组学模型可作为术前无创预测KRAS突变的辅助参考,但当前证据尚不足以替代组织检测。
  • 阅片时需注意研究间方法学异质性大,模型预测效能中等,不宜直接用于临床决策。

局限性

  • 纳入研究平均RQS评分仅9.55分(总分26.5%),方法学质量有待提高。
  • 多数研究缺乏多中心外部验证,模型泛化能力不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The purpose of this study was to evaluate the methodological quality of radiomics-based studies for noninvasive, preoperative prediction of Kirsten rat sarcoma (KRAS) mutations in patients with colorectal cancer; furthermore, we systematically evaluate the diagnostic accuracy of predicting models.

METHODS: We systematically searched PubMed, Embase, Cochrane Library and Web of Science databases up to 20 April 2022 for eligible studies. The methodological quality of included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) and Radiomics Quality Score (RQS) tools. A meta-analysis of studies on the prediction of KRAS status in colorectal cancer patients was performed.

RESULT: Twenty-nine studies were identified in the systematic review, including three studies on the prediction of KRAS status in colorectal cancer liver metastases. All studies had an average RQS score of 9.55 (26.5% of the total score), ranging from 3 to 17. Most studies demonstrated a low or unclear risk of bias in the domains of QUADAS-2. Nineteen studies were included in the meta-analysis, mostly imaged with magnetic resonance imaging (MRI), followed by computed tomography (CT), positron emission tomography-CT (PET/CT). With pooled sensitivity, specificity and area under the curve (AUC) of the training cohorts were 0.80(95% confidence interval(CI), 0.75-0.84), 0.80(95% CI, 0.74-0.85) and 0.87(95% CI, 0.84-0.90),respectively. The pooled sensitivity, specificity, and AUC for the validation cohorts (13 studies) were 0.78(95% CI, 0.71-0.84), 0.84(95% CI, 0.74-0.90), and 0.86(95% CI, 0.83-0.89), respectively.

CONCLUSION: Radiomics is a potential noninvasive technology that has a moderate preoperative diagnosis and prediction effect on KRAS mutations. However, it has not been implemented as a clinical decision-making tool. Future researchers should pay more attention to the methodological quality of the study and further externally validate the model using multicenter datasets.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Jia, Zhao, Zhao, et al. Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: A systematic review and meta‑analysis. Eur J Radiol. 2022. PMID: 36525703. doi:10.1016/j.ejrad.2022.110640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。